A Practitioner’s Guide to Prescribing Levetiracetam for Adults with Intellectual Disabilities
We developed this levetiracetam guideline using drug prescribing information and reviewing the available literature on relevant neuropsychiatric disorders in populations without intellectual disabilities because of the dearth of available literature on the population with intellectual disabilities. This guideline includes indications, contraindications, assessments prior to and during treatment, dosing with particular focus on dosing modifications required by drug–drug interactions or personal characteristics, and adverse drug reactions. The procedures contained in this guideline may not fully account for all of the possible risks of treatment in this population because of the limited studies available; thus, there will be a need to periodically update this guideline as new information becomes available. Nevertheless, we believe that this guideline provides a useful resource for clinicians who treat epilepsy in adult individuals with intellectual disabilities. A levetiracetam drug utilization review that summarizes this guideline is described.
KeywordsSuicidal Ideation Intellectual Disability Therapeutic Drug Monitoring Angelman Syndrome Myoclonic Seizure
- Bootsma, H. P., Aldenkamp, A. P., Diepman, L., Hulsman, J., Lambrechts, D., Leenen, L., et al. (2006). The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia, 47(Suppl 2), 24–27.PubMedCrossRefGoogle Scholar
- Brockmöller, J., Thomsen, T., Wittstock, M., Coupez, R., Lochs, H., & Roots, I. (2005). Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clinical Pharmacology and Therapeutics, 77, 529–541.PubMedCrossRefGoogle Scholar
- Chaisewikul, R., Privitera, M. D., Hutton, J. L., Marson, A. G. (2001). Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. The Cochrane Database of Systematic Reviews, 1, CD001901.Google Scholar
- Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2009). Drug information handbook (18th ed.). Hudson, OH: Lexi-Comp Inc.Google Scholar
- Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., et al. (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America, 101, 9861–9866.PubMedCrossRefGoogle Scholar
- Mecarelli, O., Vicenzini, E., Pulitano, P., Vanacore, N., Romolo, F. S., Di Piero, V., et al. (2004). Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. The Annals of Pharmacotherapy, 38, 1816–1822.PubMedCrossRefGoogle Scholar
- Patsalos, P. N., Berry, D. J., Bourgeois, B. F., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., et al. (2008). Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 49, 1239–1276.PubMedCrossRefGoogle Scholar
- UCB Inc. (2009a). Keppra-levetiracetam tablet, film coated. Keppra-levetiracetam solution. (prescribing information). Smyrna, GA: UCB Inc.Google Scholar
- UCB Inc. (2009b). Keppra XR (levetiracetam) tablet, film coated, extended release tablets for oral use (highlights of prescribing information). Smyrna, GA: UCB Inc.Google Scholar
- US Department of Mental Health and Human Services. (2008). Statistical review and evaluation: Antiepileptic drugs and suicidality. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. Accessed 5 April 2011.